The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status

Background: KRAS mutations have a significant role in the consecutive activation of RAS-RAF-MEK-ERK pathway in colorectal cancer. Approximately 30-35% of sporadic colorectal cancers have KRAS mutation. While the predictive role of KRAS is commonly accepted at the present time, its prognostic role and association with different clinical and histopathological properties are currently unclear and inconsistent. The intent of this study, has been to evaluate the associations between KRAS gene mutations and clinicopathological features and survival times in Turkish colorectal cancer patients